Becton, Dickinson and Co. | BDX - Assets


Becton, Dickinson and Co. reported $50.79B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Abbott USD 108.25B 968M Sep/2026
Agilent USD 13.97B 902M Jun/2026
Align Technology USD 6.52B 103.03M Sep/2026
AngioDynamics USD 269.68M 4.04M Sep/2025
Baxter International USD 19.41B 377M Sep/2026
Becton, Dickinson and Co. USD 50.79B 60M Sep/2026
Bio-Rad Laboratories USD 10.78B 531.1M Sep/2026
Boston Scientific USD 45.46B 245M Sep/2026
Cooper Companies USD 12.67B 191.1M Jun/2026
Danaher USD 93.28B 914M Sep/2026
Dentsply International USD 5.19B 14M Sep/2026
Dexcom USD 6.24B 216.5M Sep/2026
Edwards Lifesciences USD 14.14B 277.3M Sep/2026
Globus Medical USD 5.53B 39.93M Sep/2026
Insulet USD 3.42B 250M Sep/2026
Integra LifeSciences USD 3.51B 55.69M Sep/2026
Intuitive Surgical USD 19.35B 1.53B Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Medtronic USD 93.31B 278M Jun/2026
Solventum Corp USD 14.16B 78M Sep/2026
Stryker USD 47.25B 683M Sep/2026
Tandem Diabetes Care USD 1.16B 5.29M Sep/2026
Teleflex USD 6.35B 438.92M Sep/2026
Terumo JPY 2.37T 61.86B Jun/2026
Thermo Fisher Scientific USD 114.23B 1.06B Sep/2026
Zimmer Biomet Holdings USD 23.54B 740.8M Sep/2026